Clinical Trials Directory

Trials / Completed

CompletedNCT04857697

Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial evaluates whether engineering gut microbiome using probiotics will alter the body's immune system to react to stage I-III breast or lung cancers that can be removed by surgery (operable). Having diverse species of bacteria inside the bowel may help improve the immune system, particularly the ability of the immune system to recognize cancer. Taking probiotics may change the diversity and make up of the bacteria in the bowels, and change how the immune system reacts to breast or lung cancer.

Detailed description

PRIMARY OBJECTIVES: I. To conduct a pilot study of probiotics prior to surgery in operable breast and lung cancer patients. II. To evaluate systemic and intratumoral immunomodulatory effects of probiotics in operable breast and lung cancer patients. OUTLINE: Patients undergo collection of blood samples at baseline and time of surgery, and collection of stool samples at baseline and after completion of probiotic regimen. Patients receive probiotics orally (PO) once on day 1, and then twice daily (BID) or three times daily (TID) for 2-4 weeks before standard of care surgery. Patients also undergo collection of tissue samples during standard of care surgery.

Conditions

Interventions

TypeNameDescription
PROCEDUREBiopsyUndergo biopsy
PROCEDUREBiospecimen CollectionUndergo collection of blood, stool, and tissue samples
DRUGProbioticGiven PO
PROCEDURETherapeutic Conventional SurgeryUndergo standard of care surgery

Timeline

Start date
2021-07-01
Primary completion
2023-03-08
Completion
2023-03-08
First posted
2021-04-23
Last updated
2023-04-21

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04857697. Inclusion in this directory is not an endorsement.